デフォルト表紙
市場調査レポート
商品コード
927856

サイトメガロウイルス治療の世界市場:成長、動向、予測(2022年~2027年)

Cytomegalovirus Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 111 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=130.29円
サイトメガロウイルス治療の世界市場:成長、動向、予測(2022年~2027年)
出版日: 2022年01月17日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 111 Pages
納期: 2~3営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界のサイトメガロウイルス(CMV)治療市場は、予測期間中に約6.1%のCAGRで成長すると予想されています。 CMV網膜炎と先天性CMV感染の有病率の上昇、CMV治療の適用範囲の拡大、これらの疾患の治療と診断についての認識を高めるための取り組みの増加、新薬開発のための臨床試験の増加が市場の成長を牽引する可能性があると見られます。 アメリカ疾病管理予防センター(CDC)によると、200人の乳児の約1人に先天性CMV感染症が見られ、新生児におけるCMV感染は、成人における同様の感染に関連する弱毒化したインターフェロン応答を生成します。サイトメガロウイルス感染およびサイトメガロウイルス感染の再活性化のリスクは妊娠中に報告されており、これらは先天性CMV感染につながることもあります。したがって、このような病気の負担の増加は治療の普及率を上昇させることが予想されています。

さらに、免疫系の衰弱によるエイズ患者のウイルス感染の有病率の増加は、サイトメガロウイルス薬の需要を後押しすると予想されます。たとえば、CDCが発表したデータによると、2017年には約3,670万人がHIV感染症を抱えており、この病気を治療する抗ウイルス薬の幅広い利用可能性により、効率的な治療ソリューションへの需要が高まると予想されます。

さらに、市場は予測期間中に多くの医薬品の特許満了を目撃する可能性があります。特許の満了により、後発医薬品が入手可能になります。ジェネリック医薬品は、ブランド化された医薬品と同じ薬物構成を持っていますが、非常に低価格で入手でき、費用効果が高いため、医師はこれらの薬を患者に処方します。さらに、標的疾患の診断と治療をカバーする前向きな償還シナリオは、市場の成長を促進することが期待されています。

ただし、サイトメガロウイルス薬に関連する副作用とリスクは、サイトメガロウイルス(CMV)治療市場の需要を妨げる可能性があります。

当レポートは世界のサイトメガロウイルス(CMV)治療市場について調査しており、市場機会や動向、成長および抑制要因、セグメント別や地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

  • 調査の前提条件
  • 調査範囲

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概要
  • 市場成長要因
    • 認知度の向上と新薬療法のイントロダクション
    • エイズ患者における感染症の高い有病率
    • CMV網膜炎および先天性CMV感染の患者数の急増
  • 市場抑制要因
    • サイトメガロウイルス薬に関連する副作用とリスク
  • ポーターのファイブフォース分析
    • 新規参入の脅威
    • バイヤー/消費者の交渉力
    • サプライヤーの交渉力
    • 代替製品の脅威
    • 競争の激化

第5章 市場区分

  • 用途別
    • 幹細胞移植
    • 臓器移植
    • 先天性CMV感染
    • その他
  • 流通チャネル別
    • 病院薬局
    • 小売薬局
    • 電子商取引
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ地域
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Chimerix
    • Clinigen Group plc
    • F. Hoffmann-La Roche Ltd
    • Fresenius Kabi Canada
    • Genentech, Inc.
    • Gilead Sciences
    • Merck & Co., Inc
    • Mylan NV
    • Teva Canada Limited
    • Thermo Fisher Scientific

第7章 市場機会および将来動向

目次
Product Code: 68379

The cytomegalovirus (CMV) treatment market is anticipated to register a CAGR of nearly 6.1% during the forecast period.

Key Highlights

  • Rising prevalence of CMV retinitis and congenital CMV infection, broaden the application range of CMV treatment, rising initiatives for creating awareness about treatments and diagnosis of these conditions, and increasing clinical trial studies for the development of new drugs are likely to be the factors responsible for the growth of this market.
  • As per the Centers of Disease Control and Prevention, about one out of every 200 babies is born with congenital CMV infection. CMV infection in the neonate generates attenuated interferon response associated with a similar infection in the adult. Cytomegalovirus infection and risk of reactivation of cytomegalovirus infection have been reported during pregnancy. These can also lead to congenital CMV infection. Thus, rising disease burden is expected to boost the penetration rate of treatments.

In addition, increasing prevalence of viral infections among AIDS patients due to weakened immune systems is expected to drive the demand for cytomegalovirus drugs. For instance, according to data published by the CDC, around 36.7 million people were living with HIV infection in 2017. The wide availability of antiviral drugs to treat this ailment is expected to drive the demand for efficient treatment solutions.

Furthermore, the market is likely to witness the patent expiration of many drugs during the forecast period. The expiry of patents results in the availability of generic drugs, which have the same drug constitution as branded drugs but are available at a very low price. In addition, physicians also prescribe these drugs to patients as they are cost-effective. Furthermore, a positive reimbursement scenario that covers the diagnosis and treatments of targeted disorders is expected to propel the market growth.

However, adverse effects and risks related to cytomegalovirus drugs may hamper the demand for cytomegalovirus (CMV) treatment market.

Key Market Trends

Stem Cell Transplantation Held The Substantial Share In the Market and is Expected to Continue to Do the Same during the Forecast Period

  • The stem cell transplantation poised to benefit from the inclusion of new cell types, which in turn, provide substantial opportunities to companies to reinforce their market position. As a result, the number of companies involved in cell therapy development has increased tremendously over the past years.
  • Rising funding from the government as well as private organizations to support stem cell therapy clinical trials, introduction of effective guidelines for stem cell therapy manufacturing, and proven effectiveness of products are some of the primary growth stimulants for the market. In addition, declining prices of stem cell therapies are leading to increased inclination of buyers towards cell therapy.
  • Development of cell banking facilities and resultant expansion of production, storage, and characterization of cells are enhancing volumetric capabilities of the cytomegalovirus (CMV) treatment market at a global level.
  • Furthermore, regulatory bodies are engaged in providing support to innovators for the introduction of novel and effective solutions for patients as quickly as possible. Moreover, existing companies are working in collaboration with regulatory agencies in order to best fit into the regulatory model for cell therapies.
  • Healthcare practitioners are making significant use of stem cells derived from bone marrow or blood in transplant procedures for the treatment of patients with cancer, blood disorders, and immune-related disorders. Despite being slightly ethically as well as legally controversial, the segment is gaining significant attention from entities involved in various aspects of disease management.
  • In addition, congenital CMV infection segment is expected to witness a lucrative growth over the forecast period owing to increasing incidence of the disease in neonates developed during in the prenatal period. According to the CDC, it is the most common infectious ailment cause of birth defects in the United States. About 1 out of 5 babies with congenital CMV infection will have birth defects or other long-term health problems, such as hearing loss. These infection can be cured by antiviral medications, primarily valganciclovir, may improve hearing and developmental outcomes. This is also expected to contribute towards the segment growth.

North America Represents the Largest Market and Asia-Pacific is Expected to Register Fastest Growth.

North America is projected to hold the largest share in the global market throughout the forecast horizon. Strong regulatory framework for promoting cellular therapy development, high cost of treatment in the U.S., and presence of a raft of major biotechnology companies are promoting the growth of the regional market. The U.S. is estimated to be the leading revenue contributor in research as opposed to other countries owing to the exceptional research quality, extensive government funding, and increasing research in the area.

The Asia Pacific market is anticipated to experience the highest growth during the same period. Rising investments by developers and consumers in educating themselves for advanced medicinal therapies are expected to stimulate the growth of the market in emerging economies of this region. In addition, strong product pipelines in cell-based therapies and a large patient population is expected to accelerate revenue generation in the global market. Pricing of stem cell transplant varies from region to region. For instance, cost of transplantation in the U.S. is observed to be costlier than that in Germany or China. This would lead to higher revenue generation by reducing healthcare cost in the global market.

Competitive Landscape

The market is observed to be highly competitive owing to the presence of local as well as global players. The major players include companies such as F. Hoffmann-La Roche Ltd, Fresenius Kabi Canada, Genentech, Inc., Gilead Sciences, Merck & Co., Inc, Teva Canada Limited, Thermo Fisher Scientific.

Companies are undertaking efforts for the expansion of customer base, by promoting it to patients for usage in cytomegalovirus (CMV) infection and disease treatment. For example, MERCK & CO conducted "The Merck Access" Program for PREVYMIS drug insurance coverage for patients. Post this, the company began channelizing its strategies to increase the number of patients for its products in treatment procedures.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Awareness and Introduction of New Drug Therapies
    • 4.2.2 High Prevalence of Infectious Diseases Among AIDS Patient
    • 4.2.3 Upsurge in Patient Pool of CMV Retinitis and Congenital CMV Infection
  • 4.3 Market Restraints
    • 4.3.1 Adverse Effects and Risks Related to Cytomegalovirus Drugs
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Application
    • 5.1.1 Stem Cell Transplantation
    • 5.1.2 Organ Transplantation
    • 5.1.3 Congenital CMV Infection
    • 5.1.4 Other Applications
  • 5.2 By Distribution Channel
    • 5.2.1 Hospital pharmacies
    • 5.2.2 Retail Pharmacies
    • 5.2.3 E-commerce
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Chimerix
    • 6.1.2 Clinigen Group PLC
    • 6.1.3 F. Hoffmann-La Roche Ltd
    • 6.1.4 Fresenius Kabi Canada
    • 6.1.5 Genentech Inc.
    • 6.1.6 Gilead Sciences
    • 6.1.7 Merck & Co. Inc
    • 6.1.8 Mylan N.V
    • 6.1.9 Teva Canada Limited
    • 6.1.10 Thermo Fisher Scientific

7 MARKET OPPORTUNITIES AND FUTURE TRENDS